Industry
Biotechnology
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Loading...
Open
16.47
Mkt cap
1.6B
Volume
1.1M
High
17.91
P/E Ratio
-5.60
52-wk high
20.31
Low
16.41
Div yield
N/A
52-wk low
12.95
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 5:32 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 7:21 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:47 am
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 7:43 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 2:00 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 10:47 am
Portfolio Pulse from Avi Kapoor
October 08, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 12:44 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.